Quick Takeaways
- This page summarizes Robert E. Waltermire's Form 4 filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
- 1 reported transaction and 0 derivative rows are listed below.
- Filing timestamp: 18 Jan 2023, 19:00.
Robert E. Waltermire - 16 Jan 2023 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)
- Signature
- /s/ Brian J. Lynch**
- Issuer symbol
- MDGL
- Transactions as of
- 16 Jan 2023
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 18 Jan 2023, 19:00:26 UTC
- Previous filing
- 24 Feb 2022
- Next filing
- 02 Mar 2023
- SEC
- View on sec.gov
Quoteable Key Fact
"Robert E. Waltermire filed Form 4 for MADRIGAL PHARMACEUTICALS, INC. (MDGL) on 18 Jan 2023."
What Changed
- Previous filing in this sequence was filed on 24 Feb 2022.
- Current net transaction value: $0.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Source Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MDGL | Common Stock | Award | $0 | +5,667 | $0.000000 | 5,667 | 16 Jan 2023 | Direct | F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, provided the Reporting Person continues in service with the Issuer on each such date. |
Remarks:
**As attorney-in-fact for Reporting Person